Cowen & Co. Kept Eastman Chemical (EMN) As Buy; Has Price Target Of $88.0000, Acceleron Pharma (XLRN)’s Sentiment Is 1.35

July 17, 2017 - By Louis Casey

Acceleron Pharma Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $1.24 billion. The Firm is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. It currently has negative earnings. The Company’s research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta , protein superfamily.

Among 14 analysts covering Eastman Chemical Company (NYSE:EMN), 8 have Buy rating, 2 Sell and 4 Hold. Therefore 57% are positive. Eastman Chemical Company has $92 highest and $73 lowest target. $85.90’s average target is 0.59% above currents $85.4 stock price. Eastman Chemical Company had 34 analyst reports since July 30, 2015 according to SRatingsIntel. Deutsche Bank maintained the stock with “Buy” rating in Friday, May 26 report. As per Wednesday, September 7, the company rating was downgraded by Citigroup. On Tuesday, August 2 the stock rating was downgraded by RBC Capital Markets to “Sector Perform”. The rating was downgraded by CLSA to “Underperform” on Monday, May 2. The firm earned “Outperform” rating on Wednesday, October 14 by RBC Capital Markets. The firm earned “Overweight” rating on Thursday, March 17 by KeyBanc Capital Markets. The stock of Eastman Chemical Company (NYSE:EMN) has “Buy” rating given on Monday, July 11 by Nomura. The company was maintained on Thursday, September 3 by Deutsche Bank. RBC Capital Markets maintained the stock with “Hold” rating in Monday, July 10 report. The rating was downgraded by Standpoint Research to “Hold” on Tuesday, January 24.

Eastman Chemical Company is an advanced materials and specialty additives company. The company has market cap of $12.49 billion. The Company’s divisions include Additives & Functional Products (AFP), Advanced Materials (AM), Chemical Intermediates (CI), and Fibers. It has a 14.35 P/E ratio. In the AFP segment, it makes chemicals for products in the coatings, tires, consumables, building and construction, industrial applications, including solar energy markets, animal nutrition, care chemicals, crop protection, and energy markets.

Since February 1, 2017, it had 0 buys, and 10 sales for $6.11 million activity. Costa Mark J sold 16,250 shares worth $1.30 million. KLING LEWIS M sold $319,520 worth of stock. HERNANDEZ ROBERT M sold $622,000 worth of Eastman Chemical Company (NYSE:EMN) on Wednesday, February 1. On Thursday, March 2 the insider CRAWFORD STEPHEN GLENN sold $306,774. ESPELAND CURTIS E had sold 17,100 shares worth $1.33 million on Friday, February 3. King Scott V. sold $636,460 worth of stock. RAISBECK DAVID W had sold 4,000 shares worth $316,720.

The stock increased 0.29% or $0.25 on July 14, reaching $85.4. About shares traded. Eastman Chemical Company (NYSE:EMN) has risen 7.60% since July 17, 2016 and is uptrending. It has underperformed by 9.10% the S&P500.

Analysts await Eastman Chemical Company (NYSE:EMN) to report earnings on July, 27 after the close. They expect $1.89 earnings per share, up 12.50% or $0.21 from last year’s $1.68 per share. EMN’s profit will be $276.42 million for 11.30 P/E if the $1.89 EPS becomes a reality. After $1.83 actual earnings per share reported by Eastman Chemical Company for the previous quarter, Wall Street now forecasts 3.28% EPS growth.

Investors sentiment increased to 1.29 in 2016 Q4. Its up 0.22, from 1.07 in 2016Q3. It improved, as 35 investors sold Eastman Chemical Company shares while 172 reduced holdings. 78 funds opened positions while 188 raised stakes. 117.35 million shares or 0.81% less from 118.31 million shares in 2016Q3 were reported. Edgemoor Inv Advsrs has invested 1.18% of its portfolio in Eastman Chemical Company (NYSE:EMN). Kj Harrison Prtnrs holds 0.9% or 30,000 shares. Johnson Fincl Group Incorporated accumulated 0.01% or 772 shares. South Dakota Investment Council, a South Dakota-based fund reported 427,113 shares. Omega Advsr accumulated 428,713 shares. Axa has 0% invested in Eastman Chemical Company (NYSE:EMN) for 13,500 shares. Bancorporation Of Montreal Can invested in 0.04% or 454,882 shares. Trexquant Investment Lp invested in 0.15% or 12,435 shares. 70,380 are held by Janus Cap Management Limited Liability. Nine Chapters Capital Mngmt Ltd Llc holds 1.84% of its portfolio in Eastman Chemical Company (NYSE:EMN) for 14,500 shares. Anderson Hoagland has 7,500 shares for 0.33% of their portfolio. Pnc Financial Grp Inc Inc holds 0.02% or 190,780 shares. Paloma Prtn Mngmt holds 12,435 shares or 0.01% of its portfolio. Rnc Ltd Liability Corp reported 0.02% stake. Deprince Race And Zollo stated it has 737,468 shares or 1.09% of all its holdings.

Analysts await Acceleron Pharma Inc (NASDAQ:XLRN) to report earnings on August, 3. They expect $-0.66 EPS, down 11.86% or $0.07 from last year’s $-0.59 per share. After $-0.66 actual EPS reported by Acceleron Pharma Inc for the previous quarter, Wall Street now forecasts 0.00% EPS growth.

Ratings analysis reveals 50% of Acceleron Pharma’s analysts are positive. Out of 2 Wall Street analysts rating Acceleron Pharma, 1 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. XLRN was included in 2 notes of analysts from September 29, 2016. Citigroup initiated it with “Neutral” rating and $40.0 target in Thursday, September 29 report. The stock has “Outperform” rating by Oppenheimer on Tuesday, December 13.